Physician profile
Stuart E Vanmeter
NPI 1962461848
$562.52
in general payments reported to CMS, 2019-2025
16 companies · $60.09 in 2025
The $60.09 reported for 2025 was more than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.78 · 2023: $143 · 2024: $348 · 2025: $60.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $117.23 | 2023-2025 | Keytruda, Lynparza |
| Regeneron Healthcare Solutions, INC. | $98.65 | 2023-2024 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $85.75 | 2023-2025 | Tagrisso |
| Puma Biotechnology, INC. | $43.69 | 2024 | |
| Novartis Pharmaceuticals Corporation | $30.24 | 2024-2025 | |
| Genentech USA, INC. | $29.64 | 2023-2024 | Tecentriq, Avastin |
| Jazz Pharmaceuticals INC. | $18.37 | 2024 | |
| Incyte Corporation | $17.68 | 2024 | Jakafi |
| Seagen INC. | $17.46 | 2023 | Tukysa |
| Daiichi Sankyo INC. | $16.23 | 2024 | Enhertu |
| Pfizer INC. | $15.67 | 2024 | |
| Adaptive Biotechnologies Corporation | $15.47 | 2024 | Clonoseq |
| Morphosys, US INC. | $15.23 | 2023 | Monjuvi |
| Amgen INC. | $14.77 | 2023 | Xgeva, Vectibix, Nplate |
| Myriad Genetic Laboratories, INC. | $14.66 | 2023 | Myrisk |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $11.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Vanmeter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.